OSAKA, Japan I December 24, 2013 I Takeda Pharmaceutical Company Limited (“Takeda”) announced today that it has entered into agreements with Medicines for Malaria Venture (“MMV”) to study DSM265 and ELQ300, two anti-malarial compounds, with the support of the Global Health Innovative Technology Fund (“GHIT Fund”).
New compounds are urgently needed to fight malaria, as resistance to current medicines is growing. DSM265 and ELQ300, which kill the malaria parasite through inhibition of essential enzymes, are anti-malarial compounds with a long duration of action. DSM265 has entered clinical Phase I studies, and has so far shown a good safety profile. ELQ300, a preclinical candidate, would become an important tool in the control of malaria with the potential for low-dose cures or prophylaxis of the disease.
Under the agreement, MMV will conduct DSM265 clinical studies in collaboration with Takeda using our research and development expertise. MMV and Takeda will also collaborate to solve a challenging formulation issue for ELQ300 using Takeda’s CMC (Chemistry, Manufacturing and Controls) expertise in solid oral dosage form development.
In June 2013, with support from the GHIT Fund, Takeda began to work with Product Development Partners (PDPs)*, including MMV, in a program to screen Takeda’s drug compound library for new candidate compounds that might have the potential to be developed into new drugs for the treatment of infections particularly prevalent in developing countries, such as HIV, tuberculosis, malaria and neglected tropical diseases.
Takeda will continue to promote its efforts to contribute to global health through a variety of activities including GHIT Fund programs, with the overarching aim of realizing its mission of “striving towards better health for people worldwide through leading innovation in medicine.”
*Structures which advance developments of vaccines or new drug candidates through collaboration with private organizations, international organizations, and governments of developed and developing countries and charities, etc.
About GHIT Fund
The GHIT Fund is a public-private partnership between five Japanese pharmaceutical companies (Astellas Pharma Inc.; Daiichi Sankyo Company, Limited; Shionogi & Co., Ltd.; Eisai and Takeda), two government ministries and the Bill & Melinda Gates Foundation, launched in April 2013 with a potential five-year commitment of over US$100 million. It is the first fund to involve a consortium of pharmaceutical companies, government and civil society working together to support research and development for neglected diseases. The combination of Japan’s government and its pharmaceutical industry?the third largest in the world?brings a powerful engine of knowledge and innovation to the development of medications for the developing world.
About MMV
MMV is a leading product development partnership (PDP) in the field of antimalarial drug research and development working towards the vision of a malaria-free world. Its mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs. Since its foundation in 1999, MMV has developed and brought to registration four new medicines with partners from over 300 pharmaceutical, academic and endemic-country partners in 50 countries. With its partners MMV manages the largest portfolio of antimalarial R&D projects ever assembled, encompassing over 65 projects.
Additional information about MMV is available through its website, http://www.mmv.org/
SOURCE: Takeda Pharmaceutical
Post Views: 220
OSAKA, Japan I December 24, 2013 I Takeda Pharmaceutical Company Limited (“Takeda”) announced today that it has entered into agreements with Medicines for Malaria Venture (“MMV”) to study DSM265 and ELQ300, two anti-malarial compounds, with the support of the Global Health Innovative Technology Fund (“GHIT Fund”).
New compounds are urgently needed to fight malaria, as resistance to current medicines is growing. DSM265 and ELQ300, which kill the malaria parasite through inhibition of essential enzymes, are anti-malarial compounds with a long duration of action. DSM265 has entered clinical Phase I studies, and has so far shown a good safety profile. ELQ300, a preclinical candidate, would become an important tool in the control of malaria with the potential for low-dose cures or prophylaxis of the disease.
Under the agreement, MMV will conduct DSM265 clinical studies in collaboration with Takeda using our research and development expertise. MMV and Takeda will also collaborate to solve a challenging formulation issue for ELQ300 using Takeda’s CMC (Chemistry, Manufacturing and Controls) expertise in solid oral dosage form development.
In June 2013, with support from the GHIT Fund, Takeda began to work with Product Development Partners (PDPs)*, including MMV, in a program to screen Takeda’s drug compound library for new candidate compounds that might have the potential to be developed into new drugs for the treatment of infections particularly prevalent in developing countries, such as HIV, tuberculosis, malaria and neglected tropical diseases.
Takeda will continue to promote its efforts to contribute to global health through a variety of activities including GHIT Fund programs, with the overarching aim of realizing its mission of “striving towards better health for people worldwide through leading innovation in medicine.”
*Structures which advance developments of vaccines or new drug candidates through collaboration with private organizations, international organizations, and governments of developed and developing countries and charities, etc.
About GHIT Fund
The GHIT Fund is a public-private partnership between five Japanese pharmaceutical companies (Astellas Pharma Inc.; Daiichi Sankyo Company, Limited; Shionogi & Co., Ltd.; Eisai and Takeda), two government ministries and the Bill & Melinda Gates Foundation, launched in April 2013 with a potential five-year commitment of over US$100 million. It is the first fund to involve a consortium of pharmaceutical companies, government and civil society working together to support research and development for neglected diseases. The combination of Japan’s government and its pharmaceutical industry?the third largest in the world?brings a powerful engine of knowledge and innovation to the development of medications for the developing world.
About MMV
MMV is a leading product development partnership (PDP) in the field of antimalarial drug research and development working towards the vision of a malaria-free world. Its mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs. Since its foundation in 1999, MMV has developed and brought to registration four new medicines with partners from over 300 pharmaceutical, academic and endemic-country partners in 50 countries. With its partners MMV manages the largest portfolio of antimalarial R&D projects ever assembled, encompassing over 65 projects.
Additional information about MMV is available through its website, http://www.mmv.org/
SOURCE: Takeda Pharmaceutical
Post Views: 220
